09688 ZAI LAB
- 13.000
- +0.440+3.50%
ZAI LAB News
再鼎醫藥：2023 年度報告
US Capital Group sold 1.101 million H shares of Zaiding Pharmaceutical (09688.HK) OTC, worth about US$17.1036 million
On April 29, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 29, The Capital Group Companies, Inc. (The Capital Group Companies, Inc.) sold $1.101 million H-shares worth about US$17.1036 million off the market at an average price of US$15.5472 per share on April 25. After the sale, the latest number of shares held by US Capital Group was 78.5925 million shares, and the good position ratio fell from 8.03% to 7.92%. Photo source: What does the Stock Exchange's shares disclose
Zai Lab Limited's (NASDAQ:ZLAB) Revenues Are Not Doing Enough For Some Investors
With a price-to-sales (or "P/S") ratio of 5.9x Zai Lab Limited (NASDAQ:ZLAB) may be sending very bullish signals at the moment, given that almost half of all the Biotechs companies in the United State
Zaiding Pharmaceutical (09688.HK) plans to hold a board meeting on May 9 (Hong Kong time) to approve the first quarter results
Gelonghui, April 26, 丨 Zaiding Pharmaceutical (09688.HK) announced that the Board Review Committee will review and approve (including) the unaudited quarterly results (“First Quarter Results”) of the Company and its subsidiaries for the 3 months ended March 31, 2024, prepared in accordance with US GAAP and applicable rules of the US Securities and Exchange Commission (“First Quarter Results”). If the first quarter results are approved by the Audit Committee, the company will do so on Wednesday, May 8, 2024 (US)
再鼎醫藥：審核委員會行動通告及2024年第一季度業績公告的發佈日期
Changes in US stocks | Zaiding Pharmaceutical rose more than 5%, and the former vice president of Xiansheng Pharmaceutical will join the company as the chief commercial officer in Greater China
On April 24, Gelonghui | Zaiding Pharmaceutical (ZLAB.US) rose more than 5% to $15.88. On April 22, Zhu Tong, the former vice president of Xiansheng Pharmaceutical, joined Zaiding Pharmaceutical as the Chief Commercial Officer of Greater China. Liang Yi, the current Chief Commercial Officer and President of Greater China, will leave office on April 30. Zaiding Pharmaceutical has confirmed the news to the media. According to data, Zhu Tong has extensive experience in pharmaceutical marketing and has worked for well-known multinational pharmaceutical companies such as AstraZeneca, Roche, and Sanofi.
According to Interface News, Zhu Tong, the chief operating officer of Qiansheng Zaiming and senior vice president of Xiansheng Pharmaceutical, joined Zaiding Pharmaceutical as the Chief Commercial Officer of Greater China today. Liang Yi, the current chie
According to Interface News, Zhu Tong, the chief operating officer of Qiansheng Zaiming and senior vice president of Xiansheng Pharmaceutical, joined Zaiding Pharmaceutical as the Chief Commercial Officer of Greater China today. Liang Yi, the current chief commercial officer of Zaiding Pharmaceutical and president of Greater China, will leave Zaiding Pharmaceutical on April 30. On the same day, Zaiding Pharmaceutical confirmed the above information but did not further explain the personnel changes in this position in the company.
Zai Lab Files Automatic Ordinary Shares Offering
Asian Equities Traded in the US as American Depositary Receipts Remain Flat in Wednesday Trading
After opening the trading session in positive territory, Asian equities traded in the US as American depositary receipts fell flat Wednesday morning, declining 0.061% to 1,823.73 on the S&P Asia 50 AD
Press Release: Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024
Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024 - Company to Host Conference Call and Webcast on May 9, 2024, at 8:00 a.m. ET (8:00 p.m. HKT) SHA
Zai Lab Executives to Maintain Current Shareholdings
Zai Lab CEO, Others 'Do Not Anticipate' Selling Company Shares in Remainder of 2024
Zai Lab (ZLAB) said Thursday that Chief Executive Officer Samantha Du and some others on executive management team have agreed that they "do not anticipate" selling any company shares through the rema
Zai Lab Statement on Executive Management Team's Agreement on Share Activities
The Executive Officers of Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)), Samantha Du, Josh Smiley, Rafael Amado, Harald Reinhart, Yajing Chen, F. Ty Edmondson, as well as Jonathan Wang, today announced that they have each
Zai Lab Changes Record Date
Zai Lab (HKG:9688) said it changed the ordinary share record date and the ADS record date, according to a Wednesday filing on the Hong Kong bourse. The ordinary share record date changed to Thursday,
Analysts' Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Zai Lab (ZLAB) and Idexx Laboratories (IDXX)
Zai Lab(ZLAB.US) Officer Sells US$31,157.92 in Common Stock
$Zai Lab(ZLAB.US)$ Officer Smiley Joshua L sold 1,988 shares of Common Stock on Apr 4, 2024 at an average price of $15.673 for a total value of $31,157.92.Source: Announcement What is statement of cha
Zai Lab(ZLAB.US) Officer Sells US$32,991.67 in Common Stock
$Zai Lab(ZLAB.US)$ Officer Reinhart Harald sold 2,105 shares of Common Stock on Apr 4, 2024 at an average price of $15.673 for a total value of $32,991.67.Source: Announcement What is statement of cha
Zai Lab(ZLAB.US) Officer Sells US$19,497.21 in Common Stock
$Zai Lab(ZLAB.US)$ Officer Edmondson Frazor Titus III sold 1,244 shares of Common Stock on Apr 4, 2024 at an average price of $15.673 for a total value of $19,497.21.Source: Announcement What is state
Zai Lab(ZLAB.US) Officer Sells US$30,593.7 in Common Stock
$Zai Lab(ZLAB.US)$ Officer Amado Rafael sold 1,952 shares of Common Stock on Apr 4, 2024 at an average price of $15.673 for a total value of $30,593.7.Source: Announcement What is statement of changes
Zai Lab(ZLAB.US) Officer Sells US$13,243.69 in Common Stock
$Zai Lab(ZLAB.US)$ Officer Chen Yajing sold 845 shares of Common Stock on Apr 4, 2024 at an average price of $15.673 for a total value of $13,243.69.Source: Announcement What is statement of changes i
Analysis
Price Target
No Data
